Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Barchart

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

Investors Business Daily

Novo Nordisk To Up Production Capacity As Parent Buys Catalent

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Stock Surges Out Of A Buy Zone On Ozempic's Commanding Sales Beat

Novo Nordisk stock popped Wednesday after its biggest moneymaker, a diabetes drug called Ozempic, put up a commanding fourth-quarter beat.

Investors Business Daily

Wall Street Raises The Bar For These Four Stocks In 2024

Nvidia is one of four stocks with rising profit estimates for 2024. Others are MercadoLibre, Deckers Outdoor and Novo Nordisk.

Investors Business Daily

Novo Nordisk, IBD Stock Of The Day, Flashes Buy Signal Amid The Weight-Loss Craze

Novo Nordisk stock is Friday's IBD Stock Of The Day. Shares are in a buy zone after the firm inked deals in the weight-loss drugs space.

Investors Business Daily

Stock Market Skids To Start 2024 As Tesla, Apple Stumble, Mobileye Crashes: Weekly Review

The S&P 500 snapped a nine-week win streak, but tried to find support. Tesla, Apple and Mobileye were key losers.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Investors Business Daily

Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity

Novo Nordisk inked a pair of deals Thursday to bolster its weight-loss drugs franchise, and sent shares of Omega into the stratosphere.

Investors Business Daily

Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives

Novo Nordisk stock skidded Tuesday after Eli Lilly's weight-loss drug outperformed Novo's rival medication in a first-of-its-kind study.

Investors Business Daily

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

Weight-loss drug Wegovy faces high demand, limited supply, and tricky health care systems to navigate.

Fortune

Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues

Novo Nordisk stock is Thursday's IBD Stock Of The Day after a study showed weight-loss drug, Wegovy, cut down on heart attacks and strokes.

Investors Business Daily

Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.

Fortune

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

Fortune

Novo Nordisk isn’t alone: Sales of Wegovy rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

Investors Business Daily

Novo Crushes Forecasts As Sales Of Weight-Loss Drug Rocket Eightfold

Novo Nordisk stock gapped up Thursday after reporting sweeping growth for weight-loss drug Wegovy, though Ozempic sales missed.

Fortune

Novo Nordisk gives foodmakers $900 million reason to worry

Sales would have been higher if not for a shortfall following surging demand.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Sales soar at Danish firm behind weight-loss drug semaglutide

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company

Investors Business Daily

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?

The good times keep rolling for Novo Nordisk and its weight-loss drugs. But it's bad news for some medical device stocks.

Investors Business Daily

Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review

The major indexes rallied for the week, but hit resistance at key levels amid weak stock market breadth. Novo Nordisk, JPMorgan, Exxon were in focus.

Investors Business Daily

Why Novo's Good News For Ozempic Slammed Dialysis Stocks DaVita And Fresenius

Novo Nordisk stock popped Wednesday after the company hinted Ozempic showed early promise in kidney disease treatment.

Fortune

Wall Street is now betting against restaurant stocks because of Novo Nordisk’s Ozempic and high interest rates

Short positions on companies such as McDonald’s and Starbucks have increased in the last month, and weight loss drugs are part of the reason why.

Fortune

Weight-loss drugs like Ozempic have so much promise a major bank is telling investors to short junk food stocks

Barclays strategists expect "disruption into a number of industries," thanks to drugs like Novo Nordisk's Ozempic and Wegovy.

Investors Business Daily

Novo Nordisk Stock Skids After FDA Inspection Turns Up Problematic Bacteria In Key Plant

Novo Nordisk found "objectionable" bacteria in several batches of semaglutide, according to an FDA report. Novo Nordisk stock fell Thursday.

1 … 3 4 5 6

People

Lars Fruergaard Jørgensen

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.